Physician profile
Mouna Bacha
NPI 1568439941
$1,528.12
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $536 · 2021: $144 · 2022: $172 · 2023: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $119.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $264.68 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $236.65 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $178.72 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.61 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $154.63 | 2019-2023 | Farxiga |
| Pfizer INC. | $116.13 | 2019-2023 | |
| Lilly USA, LLC | $102.54 | 2020-2021 | |
| Glaxosmithkline, LLC. | $65.36 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $43.01 | 2019 | |
| Astellas Pharma US INC | $41.20 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.67 | 2022 | |
| Abbvie INC. | $24.61 | 2023 | Vraylar |
| Medtronic Vascular, INC. | $19.14 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.52 | 2023 | Rexulti |
| Insmed, INC. | $17.87 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $17.71 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $17.38 | 2020 | |
| Merck Sharp & Dohme LLC | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mouna Bacha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.